Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

To our knowledge, this is the first NMA study comparing apixaban with rivaroxaban in
morbidly obese patients with AF. Our NMA showed there was no significant difference in …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background: Treatment for non-valvular atrial fibrillation (NVAF) is complicated among
morbidly obese (MO) patients. Current ISTH guidelines do not recommend direct oral …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …